Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This was a multinational, randomised, double-blind, placebo-controlled, parallel-group study
to evaluate the efficacy, safety, and tolerability of multiple doses of ESL as prophylactic
treatment in subjects with migraine with or without aura. Subjects were randomised in a 1:1:1
ratio to receive placebo, ESL 800 mg/day once daily (QD), or ESL 1200 mg/day QD.